GEN News Highlights

More »
Nov 18, 2009

Formatech to Fill and Finish One Lot of KAI Pharmaceuticals’ SHPT Drug at No Charge

    KAI Pharmaceuticals KAI-4169 will be the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.

    KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients. Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010.



GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll